| Literature DB >> 34422733 |
Giulio Ippolito1, Adriano La Vecchia1, Giulia Umbrello1, Giada Di Pietro1, Patrizia Bono2, Stefano Scalia Catenacci3, Raffaella Pinzani4, Claudia Tagliabue4, Samantha Bosis4, Carlo Agostoni5,6, Paola Giovanna Marchisio4,7.
Abstract
Background: The containment measures adopted during COVID-19 pandemic have influenced the epidemiology of other respiratory viruses. Aim: We analyzed the modification of the incidence and etiology of lower respiratory tract infections (LRTIs) in young children during COVID-19 pandemic.Entities:
Keywords: COVID-19; children; epidemiology; public health; respiratory viruses
Year: 2021 PMID: 34422733 PMCID: PMC8374241 DOI: 10.3389/fped.2021.721005
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
Viral detections, demographic characteristic and risk factors in pre-COVID-19 seasons and 2020/2021.
|
|
| ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
|
| |||||
| Female | 162 | 79 (49) | 16 | 5 (31) | 0.18 |
| Male | 162 | 83 (51) | 16 | 11 (69) | 0.18 |
| Age in months, median (IQR) | 162 | 4.3 (2–10) | 16 | 11.8 (3–16) | 0.04 |
|
| |||||
| Comorbidity | 162 | 30 (18) | 16 | 7 (44) | 0.01 |
| Prematurity | 162 | 39 (24) | 16 | 4 (25) | 1 |
| Exclusively formula milk | 152 | 63 (41) | 9 | 2 (22) | 0.31 |
| Passive smoking | 137 | 42 (31) | 4 | 0 (0) | 0.32 |
| Older siblings | 147 | 117 (80) | 16 | 10 (62) | 0.12 |
| Day-care attendante | 153 | 16 (10) | 15 | 3 (20) | 0.38 |
|
| |||||
| Negative | 162 | 5 (3) | 16 | 2 (12.5) | 0.12 |
| Positive | 162 | 157 (97) | 16 | 14 (87.5) | 0.12 |
| Single-detections | 162 | 102 (63) | 16 | 8 (50) | 0.57 |
| Co-detections | 162 | 55 (34) | 16 | 6 (37.5) | 0.57 |
| Negative | 162 | 5 (3) | 16 | 2 (12.5) | 0.12 |
Viral detections by years.
|
|
|
| |
|---|---|---|---|
|
|
|
| |
| Influenza A | 11 (17) | 2 (2) | 0 (0) |
| Influenza B | 0 (0) | 4 (4) | 0 (0) |
| Adenovirus | 4 (6) | 10 (10) | 2 (12) |
| Bocavirus | 8 (12) | 7 (7) | 2 (12) |
| Coronavirus (non SARS-CoV-2) | 3 (5) | 1 (1) | 0 (0) |
| Enterovirus | 3 (5) | 7 (7) | 1 (6) |
| Metapneumovirus | 4 (6) | 12 (12) | 0 (0) |
| Parainfluenza viruses (1;3;4) | 0 (0) | 7 (7) | 0 (0) |
| Rhinovirus | 13 (20) | 21 (22) | 14 (87) |
| RSV | 46 (70) | 62 (65) | 0 (0) |
| CMV | 2 (3) | 0 (0) | 1 (6) |
| SARS-CoV-2 | 0 (0) | 0 (0) | 2 (12) |
CMV, cytomegalovirus; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 1Cumulative respiratory viruses detections by year and viral species.
Average number of viral detections in pre-COVID-19 seasons and viral detections in 2020/2021 season for viral type.
|
|
|
| |
|---|---|---|---|
| Influenza A and B | 6.5 | 0 | 0.0015 |
| Adenovirus | 7 | 2 | 0.03 |
| Bocavirus | 7.5 | 2 | 0.02 |
| Coronavirus (non-SARS-CoV2) | 2 | 0 | 0.135 |
| Enterovirus | 5 | 1 | 0.04 |
| Metapneumovirus | 8 | 0 | 0.0003 |
| Parainfluenzae (1;3;4) | 3.5 | 0 | 0.03 |
| Rhinovirus | 17 | 14 | 0.28 |
| RSV | 54 | 0 | <0.000001 |
| CMV | 1 | 1 | 0.735 |
CMV, cytomegalovirus; RSV, respiratory syncytial virus.
P-value of the cumulative probability using one-tail Poisson distribution.
Therapies and outcomes in pre-Covid seasons and 2020/2021 season.
|
|
| ||
|---|---|---|---|
|
|
|
| |
| Antibiotics use | 102 (63) | 10 (62) | 0.97 |
| Antiviral use | 16 (10) | 2 (12) | 0.67 |
| Oxygen therapy | 135 (83) | 7 (44) | 0.046 |
| CPAP | 35 (22) | 1 (6) | 0.2 |
| HFNC | 88 (54) | 6 (37) | 0.2 |
| Salbutamol aerosol | 145 (89) | 12 (75) | 0.1 |
| Mechanical ventilation | 7 (4) | 0 (0) | 1 |
| Hospitalization days, median (IQR) | 6 (5–8) | 4 (4–6) | 0.006 |
CPAP, continuous positive airway pressure; HFNC, high-flow nasal cannula.